Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma
Status:
Terminated
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
This study is to determine whether addition of Revlimid to standard therapy will increase
overall and complete response rates compared to historical standard frontline therapy and
whether this combination treatment has fewer side effects than similar combination induction
treatment.
Phase:
Phase 2
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health